At the end of 2020, many of us reflected on the huge successes that the Biotech industry had experienced with obtaining IPO funding; we did not expect to see it continue long into 2022. However, it has, and an astonishing number of Biotech firms are enjoying large amounts of funding when they take their company public.
Continue reading “The Glut of Funding Available When Biotech’s Choose to Go Public”
In recent years, the world has faced significant challenges, from the ongoing pandemic to social injustices exemplified by tragic events like the deaths of George Floyd, Ahmaud Arbery, and Daunte Wright. These events have spurred a heightened awareness of inequalities, prompting a collective push towards creating a more equitable society. In the Life Science community, many companies are committed to diversifying their leadership teams and boards but struggle to identify suitable candidates. Discover how a recruitment service like GeneCoda® can play a pivotal role in achieving diversity in leadership teams.
Continue reading “Achieving Diversity in Your Leadership Team – How a Recruitment Firm Can Help”
In this series on qualifying search firms, we’ve covered various aspects of choosing the right partner. Today, our focus shifts to understanding the crucial elements of search firm fees, expenses, and guarantees, particularly in retained search. This type of recruitment is geared towards passive candidates, ensuring thorough consideration of their qualifications and fit. For a deeper understanding, you can also explore our YouTube series detailing the differences between retained and contingency firms.
Continue reading “Qualifying Search Firms – Fees, Expenses, and Guarantees”
As the Omicron variant emerged, initial concerns arose regarding its potential impact compared to the Delta variant. Recent developments suggest it may pose even greater challenges. In this article, we explore the Omicron impact in 2022, evolving implications of the Omicron variant as it unfolds in the coming weeks.
Continue reading “Keeping an Eye on Omicron – Where it May Lead in 2022”
In this series, we’ve been examining the most important aspects to consider when selecting a search firm. Today we’ll cover questions around search firm value adds.
The subject of retirement is often discussed by Life Science executives, especially with the ongoing pressure to offer more solutions and support to the global market. The concern that many of us face is the impact of this wave when people have left their positions and how the industry will cope with finding new people to replace them. Let’s take a look at some of the key reasons executives feel the need to leave and learn more about how we can help.
Continue reading “How to Handle a Growing Wave of Executive Retirements”
In this series, we’ve been outlining the considerations involved when selecting a search firm. Today, we’ll cover questions around search firm benchmarks.
There is no denying the fact that the Life Science industry is in high demand as we all look for improvements in our lives, wanting answers and solutions that can revolutionize our health. With that demand comes a world that is constantly changing and improving, but how can we work out where our focus needs to be and what is better left for the future? We took a look at some of the biggest trends in Life Science right now in a bid to work out where we are headed.
In our “Qualifying Search Firms” series, we’ve been sharing everything one should know to select a high-quality search firm. Today, we’ll cover questions around search firm capacity.
Continue reading “Qualifying Search Firms – Search Firm Workload”
The Life Science industry is facing more demand for information than ever before. Despite a global staffing shortage, more companies are looking to expand their offer to meet the need. COVID-19 has boosted the amount of research money available, leaving many Life Science companies in desperate need of more space, opening up the property investment market to find suitable premises for labs, manufacturing, and office space. Continue reading “Why Property Developers and Investors Want to Work with Life Science Companies”
